Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...
Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results